KR20220019017A - ｛6-[(2-아미노-3-클로로피리딘-4-일)설파닐]-3-[(3s,4s)-4-아미노-3-메틸-2-옥사-8-아자스피로[4.5]데칸-8-일]-5-메틸피라진-2-일｝메탄올의 고체 형태인 shp2 저해제 - Google Patents

｛6-[(2-아미노-3-클로로피리딘-4-일)설파닐]-3-[(3s,4s)-4-아미노-3-메틸-2-옥사-8-아자스피로[4.5]데칸-8-일]-5-메틸피라진-2-일｝메탄올의 고체 형태인 shp2 저해제 Download PDF

Info

Publication number
KR20220019017A
KR20220019017A KR1020227000184A KR20227000184A KR20220019017A KR 20220019017 A KR20220019017 A KR 20220019017A KR 1020227000184 A KR1020227000184 A KR 1020227000184A KR 20227000184 A KR20227000184 A KR 20227000184A KR 20220019017 A KR20220019017 A KR 20220019017A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
crystalline form
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227000184A
Other languages
English (en)
Korean (ko)
Inventor
샤오링 리
스티븐 지. 발머
Original Assignee
레볼루션 메디슨즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레볼루션 메디슨즈, 인크. filed Critical 레볼루션 메디슨즈, 인크.
Publication of KR20220019017A publication Critical patent/KR20220019017A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227000184A 2019-06-07 2020-06-04 ｛6-[(2-아미노-3-클로로피리딘-4-일)설파닐]-3-[(3s,4s)-4-아미노-3-메틸-2-옥사-8-아자스피로[4.5]데칸-8-일]-5-메틸피라진-2-일｝메탄올의 고체 형태인 shp2 저해제 Ceased KR20220019017A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962858837P 2019-06-07 2019-06-07
US62/858,837 2019-06-07
PCT/US2020/036137 WO2020247643A1 (en) 2019-06-07 2020-06-04 Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Publications (1)

Publication Number Publication Date
KR20220019017A true KR20220019017A (ko) 2022-02-15

Family

ID=71787182

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227000184A Ceased KR20220019017A (ko) 2019-06-07 2020-06-04 ｛6-[(2-아미노-3-클로로피리딘-4-일)설파닐]-3-[(3s,4s)-4-아미노-3-메틸-2-옥사-8-아자스피로[4.5]데칸-8-일]-5-메틸피라진-2-일｝메탄올의 고체 형태인 shp2 저해제

Country Status (15)

Country Link
US (2) US11220501B2 (https=)
EP (1) EP3980128A1 (https=)
JP (2) JP2022534788A (https=)
KR (1) KR20220019017A (https=)
CN (2) CN115141205A (https=)
AU (1) AU2020288631A1 (https=)
BR (1) BR112021022635A2 (https=)
CA (1) CA3142430A1 (https=)
IL (1) IL288568A (https=)
MA (1) MA56113A (https=)
MX (1) MX2021014855A (https=)
PH (1) PH12021552902A1 (https=)
SG (1) SG11202112461QA (https=)
TW (1) TW202112785A (https=)
WO (1) WO2020247643A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
EP3980128A1 (en) 2019-06-07 2022-04-13 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
CA2606288A1 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
KR101906146B1 (ko) * 2009-08-17 2018-10-10 메모리얼 슬로안-케터링 캔서 센터 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
JP6523303B2 (ja) * 2014-01-17 2019-05-29 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物
KR102598895B1 (ko) * 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
SG11202009793TA (en) 2018-04-10 2020-10-29 Revolution Medicines Inc Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations
EP3980128A1 (en) * 2019-06-07 2022-04-13 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Also Published As

Publication number Publication date
WO2020247643A1 (en) 2020-12-10
JP2025138706A (ja) 2025-09-25
SG11202112461QA (en) 2021-12-30
AU2020288631A1 (en) 2021-12-09
BR112021022635A2 (pt) 2022-01-04
CA3142430A1 (en) 2020-12-10
MX2021014855A (es) 2022-01-18
US12528807B2 (en) 2026-01-20
EP3980128A1 (en) 2022-04-13
MA56113A (fr) 2022-04-13
PH12021552902A1 (en) 2022-04-04
IL288568A (en) 2022-02-01
US11220501B2 (en) 2022-01-11
CN115141205A (zh) 2022-10-04
JP2022534788A (ja) 2022-08-03
US20220298159A1 (en) 2022-09-22
TW202112785A (zh) 2021-04-01
US20210253574A1 (en) 2021-08-19
CN114190090A (zh) 2022-03-15

Similar Documents

Publication Publication Date Title
KR20220019017A (ko) ｛6-[(2-아미노-3-클로로피리딘-4-일)설파닐]-3-[(3s,4s)-4-아미노-3-메틸-2-옥사-8-아자스피로[4.5]데칸-8-일]-5-메틸피라진-2-일｝메탄올의 고체 형태인 shp2 저해제
CA3098336C (en) Crystal form of c-met inhibitor and salt form thereof and preparation method therefor
CN113354649B (zh) 一种新的晶型
TWI653235B (zh) 作為抗癌劑之吲哚衍生物
US20200317657A1 (en) Solid forms of(z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
EP3439663B1 (en) Methods of treating pediatric cancers
EA015677B1 (ru) СОЛИ И КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 2-МЕТИЛ-2-[4-(3-МЕТИЛ-2-ОКСО-8-ХИНОЛИН-3-ИЛ-2,3-ДИГИДРОИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)ФЕНИЛ]ПРОПИОНИТРИЛА
US20220169615A1 (en) Amorphous and crystalline forms of ido inhibitors
CA3178415A1 (en) Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1h-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7h)-one
JP2020534331A (ja) （（１ｓ，２ｓ，４ｒ）−４−｛４−［（１ｓ）−２，３−ジヒドロ−１ｈ−インデン−１−イルアミノ］−７ｈ−ピロロ［２，３−ｄ］ピリミジン−７−イル｝−２−ヒドロキシシクロペンチル）メチルスルファメートの共結晶形態、その製剤及び使用
IL242997A (en) A nitrogenous aromatic heterocyclic compound in a bicycle containing nitrogen
JP7649241B2 (ja) Ｍｃｌ－１阻害剤の新しい結晶形、その調製プロセス及びそれらを含有する医薬組成物
HK40077975A (zh) Shp2抑制剂的固体形式
HK40068870A (en) Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
RU2844681C2 (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
US10072029B2 (en) Crystalline form of a proteasome inhibitor
BRPI0616374A2 (pt) formas de sal sólido para um pirrol substituìdo 2-indolinona, composição farmacêutica compreendendo as mesmas, método para modulação de atividade catalìtica de proteìna quinase, proteìna quinase, métodos pra preparação de cristais e de polimorfos e uso

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220104

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250312

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250516

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D